期刊文献+

化放疗综合治疗95例局限期小细胞肺癌的疗效分析 被引量:6

Chemotherapy combined with chest radiation therapy in the treatment of 95 patients with limited stage small cell lung cancer
暂未订购
导出
摘要 目的 回顾性分析 95例局限期小细胞肺癌 (limitedstagesmallcelllungcancer,LSCLC)化放疗综合治疗的疗效和影响预后的因素。方法 经病理证实的局限期小细胞肺癌 95例 ,男 84例 ,女 11例。中位年龄5 8岁 (32~ 75岁 )。按 1997年UICC的TNM分期法 ,Ⅰ期 3 % (3/95 ) ,Ⅱ期 7% (7/95 ) ,ⅢA期 5 2 % (49/95 ) ,ⅢB期 38% (36 /95 )。放疗 :照射野包括原发灶 +同侧肺门 +上纵隔 (原发灶位于上、中叶 ) /全纵隔 (原发灶位于下叶 ) ,不作锁骨上区及脑的预防性照射。肿瘤中位剂量 :5 9.1Gy(43 .8~ 76 .9Gy) /31次 (2 2~ 6 4次 ) /4 8天 (30~73天 )。放疗于化疗 1疗程后开始。化疗方案 :CAP(环磷酰胺、阿霉素、顺铂 )以及EP(依托泊甙、顺铂 )、TP(替尼泊甙、顺铂 )或IEP(异环磷酰胺、依托泊甙、顺铂 )。中位化疗疗程为 6个 (1~ 10个 )。结果 治疗结束后 2月评价近期疗效 ,完全缓解 (CR) 5 8% (5 5 /95 ) ,部分缓解 (PR) 38% (36 /95 ) ,缓解率达 96 % (91/95 )。中位生存时间为 2 8个月。 1、2、3、5年生存率分别为 85 %、6 2 %、31%、13 %。 1、2、3、5年局部控制率分别为 95 %、86 %、77%、6 4%。 1、2、3、5年远处转移率分别为 2 3%、5 2 %、73 %、83 %。Cox回归模型分析显示治疗前一般状态评分 Objective To analyse retrospectively the results and prognostic factors of 95 patients with limited stage small cell lung cancer treated with chemotherapy plus chest radiation therapy. Methods Ninetyfive patients with limited stage small cell lung cancer were treated with combination chemotherapy plus chest radiation therapy from December, 1989 to June, 1997. There were 84 males and 11 females with median age of 58 years (32~75 years). The PTNM stages of the disease were as follows: stage Ⅰ disease, 3 patients; stage Ⅱ disease, 7 patients; stage ⅢA disease, 49 patients and stage ⅢB disease, 36 patients. Chemotherapy regimens were CAP (cyclophosphamide, doxorubicin, cisplatin), EP(etoposide, cisplatin), TP(Teniposide, cisplatin), or IEP (ifosphamide, etoposide, cisplatin). Median cycles were 6 (1~10). After one cycle of chemotherapy, patients received chest radiation therapy with median total tumor dose of 59.1?Gy(43.8~76.9?Gy)/31fx(22~64?fx) for 48 days(30~73?days). The radiation fields covered tumors with 1.5~2.0?cm margins. Supraclavicular region and brain did not receive prophylactic irradiation. Results Of the ninetyfive patients, 55(58%) had a complete response, 36(38%) had a partial response, three had a stable disease and one had a disease progression. The median survival time was 28 months. The 1, 2, 3 and 5year survival rates were 85%, 62%, 31% and 13%, respectively. The 1, 2, 3, and 5year local control rates were 95%, 86%, 77% and 64%, respectively. The 1, 2, 3 and 5year distant metastasis rates were 23%, 52%, 73%, and 83%, respectively. From multivariate regression analyses, KPS≥70 and complete response and partial response could be the favorable predictors. Conclusion Chemotherapy combined with chest irradiation in limited stage small cell lung cancer can get better survival and local control and less distant metastases. KPS≥70 and complete response and partial response might be the favorable predictors.
出处 《中国肺癌杂志》 CAS 2000年第5期340-343,共4页 Chinese Journal of Lung Cancer
关键词 局限期小细胞肺癌 化学治疗 放射治疗 综合治疗 Limited stage small cell lung cancer Chemotherapy Radiotherapy Combined modality therap?
  • 相关文献

参考文献1

二级参考文献38

  • 1傅深,蒋国梁,王丽娟,钱浩,叶明,傅晓龙,赵森,何少琴,刘泰福.超分割放疗非小细胞肺癌疗效分析──临床Ⅲ期研究[J].中华肿瘤杂志,1994,16(4):306-309. 被引量:18
  • 2Dresler CM.Appropriate diagnostic evaluation.Curr Probl Cancer,1996,20(3):147.
  • 3Saunders MI.Predictive testing of radiosensitivity of non-small cell carcinoma of the lung.Lung Cancer,1994,10(Suppl):S83.
  • 4Mcdonald S,Rubin P,Phillips TL,et al.Injury to the lung from cancer therapy:Clinical syndromes,measurable endpoint.and potential scoring system.Int J Radial Oncol Biol Phys,1995,31(5):1187.
  • 5Herrmenn T,Schorcht J,Molls M(Eds).Radiation Pneurnopathy in "Late Sequelar in Oncology".Dunst J and Sauer R.Springer-Verlag,1992.135-140.
  • 6Dosoretz DE,Katin MJ.Blitzer PH,et al.Medically inoperable lung cancer:The role of radiation therapy.Sctrinar Radiat Oncol,1996,6(2):98.
  • 7Ganden S,Rarnsay J,Tripcony L.The curative treatment by radiotherapy alone of stage I non-small cell lung cancer.Chest,1995,108(5):1278.
  • 8Cox JD,Azamia N,Byhardt RW,et al.A randomized phase I/Ⅱ trial of hyperfractionated radiation therapy with total dose of 60.0Gy to 79.2Gy:Poesible benefit with 69.6Gy in favorable patients with Radiation Therapy Oncology Group atage Ⅲ non-small cell lung cancer:Report of RTOG 83.11.J Clin Oncol,1990,8(9):1543.
  • 9蒋国榛 王丽娟 傅深 等.超分割放闻非小细胞肝癌临床I/Ⅱ期试验[J].中华放谢肿瘤学杂志,1993,2(4):231-231.
  • 10Saunders MI,Dische S,Barrett A,Randomized multicentre trials of CHART vs.conventional radiotherapy in head and neck and non-small cell lung cancer:An interim report.Br J Cancer,1996,73:1455.

共引文献7

同被引文献31

  • 1王颖杰,王绿化,陈东福,周宗玫,欧广飞,梁军,张可,殷蔚伯.小细胞肺癌的三维适形放射治疗[J].中华肿瘤杂志,2005,27(9):570-572. 被引量:12
  • 2陈东福,吕纪马,周宗枚,王绿化,张宏兴,冯勤富,梁军,肖泽芬,张世平,张香茹,殷蔚伯.放射治疗在广泛期小细胞肺癌治疗中的影响[J].医学研究杂志,2006,35(4):15-17. 被引量:16
  • 3廖美林.肺癌现代治疗[M].上海:上海医科大学出版社,1998.326.
  • 4MartinDA JamesOA AllwnSL etal 徐光炜 译.临床肿瘤学[M].沈阳:辽宁教育出版社,1999.1078.
  • 5HeineHH 王洲 李厚文 译.肺癌[M].沈阳:辽宁科学技术出版社,2001.201-202.
  • 6董志伟;谷铣之.临床肿瘤学[M]北京:人民卫生出版社,2002713-715.
  • 7Huncharek M, MeGarry R. A meta-analysis of the timing of chest irradi- ation in the combined modality treatment of limited-stage small cell lung cancer[J].Oncologist,2014,9(6):665-672.
  • 8Bremnes R M, Sundstrom S, Vilsvik J, et al. Multicenter phase Ⅱ trial of paclitaxel, cisplatin, and etoposide with concurrent ra-diation for limit- ed-stage smal-1 cell lung cancer[J].J Clin 0ncol,2001,19(15):3532-3538.
  • 9Saijo N. Progress in treatmem of small cell lung cancer, role ofCPT-1 1[J]. Br J Cancer,2013,89(12):2178-2183.
  • 10JemalA,MurrayT,WardE,et al.Cancer statisties,2014.CA Cancer J Clin, 2014,55(5):10.

引证文献6

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部